2025 New Targets Series: Bladder Cancer

$4,900.00

Seagrove Partners is happy to announce the publication of the 2025 New Targets Series: Bladder Cancer report.  This is our first detailed report in the Bladder Cancer space and includes the following content:

  • Market Statistics

  • Disease Overview

  • Clinical Algorithms

  • Clinical Trials and Outcomes

  • Pipelines and Target MOAs

  • Company Overviews and Recent Events

  • Product Overviews

Seagrove Partners is happy to announce the publication of the 2025 New Targets Series: Bladder Cancer report.  This is our first detailed report in the Bladder Cancer space and includes the following content:

  • Market Statistics

  • Disease Overview

  • Clinical Algorithms

  • Clinical Trials and Outcomes

  • Pipelines and Target MOAs

  • Company Overviews and Recent Events

  • Product Overviews